Principia Biopharma
220 E Grand Ave
South San Francisco
California
94080
United States
Tel: 650-416-7700
Website: http://www.principiabio.com/
Email: info@principiabio.com
54 articles about Principia Biopharma
-
It’s not unusual for biopharma companies to end the year with a restructuring that includes job cuts. Here are some of these companies.
-
Esker Therapeutics tapped Martin Babler to helm the company after founding CEO June Lee has stepped away to pursue other opportunities.
-
Sanofi is shuttering Principia’s laboratories in San Francisco after its Phase III PEGASUS trial of rilzabrutinib for pemphigus failed to meet primary or key secondary endpoints.
-
The top three clusters from last year's list - Greater Boston, San Francisco Bay Area and San Diego - all stood their ground and maintained their rankings from the previous year.
-
Paris-based Sanofi announced its Phase III PEGASUS clinical trial of rilzabrutinib for pemphigus failed to hit primary or key secondary endpoints.
-
Patient Enrollment Concluded Early in PEGASUS Phase 3 Pemphigus Trial for RilzabrutinibTrial enrolled patients ahead of originally anticipated timeline despite COVID-19 pandemic
11/24/2020
Principia Biopharma Inc., a Sanofi company, focused on developing treatments for immune mediated diseases, today announced it has completed patient enrollment into the global Phase 3 PEGASUS trial for rilzabrutinib, an oral investigational Bruton tyrosine kinase (BTK) inhibitor.
-
Principia Announces First Patient Dosed in Phase 2A Trial of Rilzabrutinib in IgG4-Related Disease
9/17/2020
Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune mediated diseases, today announced that the first patient was dosed in an open label two-arm trial to evaluate rilzabrutinib in IgG4-related disease (RD).
-
Sanofi to acquire Principia Biopharma
8/17/2020
Adds clinically advanced oral BTK inhibitor rilzabrutinib with potential across a range of immunology and inflammation indications, complementing Sanofi's existing R&D pipeline
-
Under terms of the deal, Sanofi will acquire all of the outstanding shares of Principia for $100 per share in cash, which represents an aggregate equity value of approximately $3.68 billion.
-
Principia Biopharma Reports Second Quarter 2020 Financial Results
8/6/2020
Principia Biopharma Inc., a late-stage biopharmaceutical company focused on developing treatments for immune mediated diseases, announced financial results for the second quarter ended June 30, 2020.
-
Rumors are flying that Paris-based Sanofi has a $50 billion budget for mergers and acquisitions and is taking a look at U.S.-based biotech companies. At the top of the list, reportedly, is South San Francisco-based Principia Biopharma.
-
Principia Announces First Patient Enrolled in Sanofi’s Phase 3 Trial of SAR442168 in Relapsing Multiple SclerosisDosing of Patient Will Trigger $50 Million Milestone Payment
6/23/2020
Principia Biopharma Inc., a late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases, announced that the first patient has been enrolled in its partner Sanofi’s Phase 3 clinical trial of SAR442168 in patients with relapsing multiple sclerosis.
-
Principia Presents Updated Positive Data of Rilzabrutinib for Immune Thrombocytopenia in Ongoing Phase 1/2 Trial
6/12/2020
Oral BTK inhibitor reaches primary endpoint in 50 percent of patients treated > 12 weeks; demonstrates fast onset and durable responses
-
Principia Announces Positive Data from its Phase 2 Part B Trial in Pemphigus
6/12/2020
Clear dose-response combined with decreased daily corticosteroid usage Response rate increased with extended duration of treatment to six months while maintaining a favorable safety profile
-
Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.
-
Principia Biopharma to Hold Virtual Analyst Event to Discuss BTK Inhibition: Beyond B Cells and AntibodiesEvent scheduled for 4:00 pm ET on Tuesday, June 16th
6/3/2020
Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases, today announced that it will host a virtual analyst event to discuss Principia’s unique precision bonding technology platform,
-
Principia Announces Data Presentations of Rilzabrutinib in Patients with Immune Thrombocytopenia (ITP) at Two Upcoming Virtual Medical Meetings
5/26/2020
Principia Biopharma Inc. announced upcoming presentations at the European Hematology Association and the International Society on Thrombosis and Haemostasis congresses from Principia’s clinical program evaluating rilzabrutinib in patients with immune thrombocytopenia, a rare autoimmune disease that causes high risk for bleeding, excessive bruising, fatigue and potential for life threatening intracranial bleeding due to destruction of platelets.
-
Principia Announces AAD Late Breaker Research Presentation of its Pemphigus Phase 2 Part B Trial
5/12/2020
Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune mediated diseases, today announced an upcoming full data set presentation from the Phase 2 Part B pemphigus trial with its investigational drug rilzabrutinib. Dr. Dedee Murrell, professor and Head of the Department of Dermatology at The St. George Hospital Clinic School, University of New South Wales in Sydney,
-
Principia Biopharma Reports First Quarter 2020 Financial Results
5/6/2020
Principia Biopharma Inc., a late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases, announced financial results for the first quarter ended March 31, 2020.
-
Principia Biopharma to Present at the 2020 Bank of America Health Care Conference
5/5/2020
Principia Biopharma Inc., a late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases, announced that management will present at the 2020 Bank of America Health Care Conference on Tuesday, May 12, 2020, at 3:00pm EDT.